Saudi Arabia Generic Drugs Market Size, Share and Growth Insights

Saudi Arabia generic drugs market is projected to witness a CAGR of 7.18% during the forecast period 2024–2031, growing from USD 4.38 billion in 2023 to USD 7.62 billion in 2031. The growth of the market is supported by the rising cases of chronic diseases, increasing government initiatives, and rising investments by the key market players towards collaborations to support the introduction of various biosimilars in the country.

Why Generic Medicines Matter for You in Saudi Arabia

In Saudi Arabia, more and more people are turning to generic medicines because they are affordable, safe, and just as effective as branded drugs. When the patents of brand-name medicines expire, generic alternatives are introduced in the market. These options contain the same active ingredients, dosage, strength, and method of use as branded medicines, but they are available at a much lower cost. This makes healthcare more affordable and ensures that patients can access the treatment they need without financial strain.

The government is actively working to make generic medicines widely available and raise awareness about their benefits. By promoting their use, the healthcare system aims to balance high-quality treatment with cost efficiency, opening the door to better healthcare access for everyone.

Click Here: https://www.marketsandata.com/industry-reports/saudi-arabia-generic-drugs-market

Growing Need for Affordable Healthcare

The demand for safe and effective medicines in Saudi Arabia is rising rapidly because of the increasing number of chronic diseases, infectious conditions, and genetic disorders. For example, according to the International Diabetes Federation (IDF), nearly 5.6 million people in Saudi Arabia will be living with diabetes by 2030. For such long-term conditions, affordable medicines like generics play a critical role in ensuring patients can continue treatment without financial challenges.

Strong Government Support

The Saudi government is introducing major initiatives to expand the use of generic drugs and improve healthcare services overall. Programs such as the Healthcare Sector Transformation Program are designed to:

• Focus on disease prevention rather than just treatment.


• Encourage innovation in healthcare.


• Build a financially sustainable system.


• Make healthcare services more accessible to patients across the country.

These steps are creating new opportunities for generic medicines to become an essential part of the healthcare system.

Why Chronic Diseases Are Driving the Demand

One of the key reasons for the growing need for generic drugs is the rising number of cardiovascular diseases in Saudi Arabia. In fact, the Ministry of Health (Feb 2023) reported that cardiovascular issues are the leading cause of death from non-communicable diseases in the country.

The Saudi Heart Association (2023) also noted that the number of people suffering from these conditions is expected to rise due to several lifestyle factors, including:

• Hypertension (high blood pressure)


• Obesity


• Diabetes mellitus


• Dyslipidemia (abnormal cholesterol levels)

The modern lifestyle—such as spending more time on video games and social media, and the country’s environment that limits outdoor physical activity—has made sedentary living common. This is increasing the risks of heart disease and other chronic health problems, leading to higher demand for affordable and reliable medicines like generics.

Download Free Sample Report

Biosimilars Account for Major Market Share

The rising efforts by key market players to increase the availability of various generics in the country are boosting Saudi Arabia’s generic drugs market size and supporting the growth of the segment. In November 2023, Lupin Ltd., one of the leading transnational pharmaceutical companies across the globe, announced a partnership with Amman Pharmaceuticals Industries for exclusive commercialization and marketing of Ranibizumab in the Middle East region, including select territories of Lebanon, Saudi Arabia, UAE, Iraq, and Jordan, among other GCC countries. Ranibizumab inhibits and binds vascular endothelial growth factor A and is indicated for treating patients with macular edema following retinal vein occlusion, myopic choroidal neovascularization, diabetic retinopathy, diabetic macular edema, and neovascular (wet) age-related macular degeneration. Such efforts and collaborations are expected to provide lucrative growth opportunities for the market in the coming years.

Future Market Scenario (2024–2031F)

As per the Saudi Arabia generic drugs market analysis, the increasing cases of chronic diseases and rising efforts of the government to transform the healthcare sector and boost awareness about the quality and effectiveness of generic drugs among the population are expected to support the growth of the market. According to the estimates of the International IDF, approximately 7.5 million individuals will be living with diabetes in Saudi Arabia by 2045. Strategic collaborations by the key players of the market to boost the availability of biosimilars in the country are also expected to provide lucrative growth opportunities to the market in the coming years. Initiatives such as Vision 2030, which aims to improve the quality of life of the residents of the country by supporting global integration, boosting opportunities for growth and investment, and enhancing the efficiency of the government, are expected to support the market’s expansion in Saudi Arabia.

About Us:
Markets and Data provides a comprehensive/ panoramic understanding of markets at global, regional, and country levels. Examine changing consumer preferences, emerging challenges, underlying trends, and growth prospects to accelerate your business strategies.

Contact
Mr. Vivek Gupta
5741 Cleveland street,
Suite 120, VA beach, VA, USA 23462
Tel: +1 (757) 343–3258
Email: [email protected]
Website: https://www.marketsandata.com